Top Nanotechnology Stocks To Keep An Eye On - April 15th

Key Points

• MarketBeat highlights four nanotechnology stocks to watch — ONTO (Onto Innovation), NVEC (NVE), NNDM (Nano Dimension) and CLNN (Clene) — selected for having the highest recent dollar trading volume among nanotech names.
• Onto Innovation supplies optical metrology, lithography and process-control tools for semiconductor manufacturing; NVE makes spintronics-based sensors and couplers; Nano Dimension builds additive-manufacturing/3D-printing systems for electronic, polymer and metal parts; and Clene is a clinical-stage biotech developing the nanotherapy CNM‑Au8 in multiple Phase 2 trials.
• The article warns that while nanotech stocks can offer strong growth linked to innovation, they also carry elevated technical, regulatory and market risk, increased volatility, and typically long development timelines.

Onto Innovation, NVE, Nano Dimension, and Clene are the five Nanotechnology stocks to watch today, according to MarketBeat's stock screener tool. Nanotechnology stocks are shares of companies that develop, manufacture, or commercialize technologies and materials engineered at the nanoscale (typically 1–100 nanometers), including firms in semiconductors, advanced materials, sensors, and biotech that use nanoscale processes. For investors, these stocks can offer high growth potential tied to innovation but also carry elevated technical, regulatory, and market risk and often exhibit greater volatility and long development timelines compared with more established industries. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

Onto Innovation (ONTO)

Onto Innovation Inc. engages in the design, development, manufacture, and support of process control tools that performs optical metrology. The company offers lithography systems and process control analytical software. It also offers process and yield management solutions, and device packaging and test facilities through standalone systems for optical metrology, macro-defect inspection, packaging lithography, and transparent and opaque thin film measurements.

Read Our Latest Research Report on ONTO

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

Read Our Latest Research Report on NVEC

Nano Dimension (NNDM)

Nano Dimension Ltd., together with its subsidiaries, engages in additive manufacturing solutions in Israel and internationally. The company offers 3D printers, comprising AME systems, which are inkjet printers, that produces Hi-PEDs by depositing proprietary conductive and dielectric substances, as well as integrates in-situ capacitors, antennas, coils, transformers, and electromechanical components; micro additive manufacturing systems, a digital light processing printers (DLP) that achieves production-grade polymer and composite parts; and industrial additive manufacturing systems, that utilizes a patented foil system that fabricates ceramic and metal parts.

Read Our Latest Research Report on NNDM

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Read Our Latest Research Report on CLNN

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.